Learn how AbbVie could help you save on RINVOQ. Call 1-800-2RINVOQ or click to learn more >
Set your long-term treatment goals
When it comes to moderate to severe UC, you shouldn't have to choose between relief that's fast and relief that lasts.
think beyond symptom relief
strive for long-term remission
aim to visibly repair the colon lining
Remission is a period when someone experiences few or no UC symptoms and their colon lining has visibly improved. Your gastroenterologist can confirm if you're in remission based on the frequency of your bowel movements, a lack of bloody stools, and a visible improvement of the colon lining seen in endoscopy results. Consider treatment options that offer lasting remission, even at 1 year.
A reduction in inflammation affecting the lining of the colon. This helps allow the colon lining to repair.
Remember that a key goal of UC treatment is to achieve steroid-free remission. It’s important to find a treatment option that can help you move toward remission and stay in remission without the need for steroids.
You should know the potential benefits and risks of RINVOQ before making any treatment decisions. Learn more about side effects.
With RINVOQ, many people achieved remission—without the need for steroids—at 1 year.
What might remission and colon lining repair look like in your day-to-day life? Do your UC symptoms keep you from doing things you enjoy? Maybe you're interested in taking a camping trip, or want to run errands without constant bathroom breaks.
That's why setting the right treatment goals can make all the difference.
The first step is talking to your gastroenterologist about the importance of achieving both lasting remission and visible repair of the colon lining.
Meet real patients who were all looking to put their UC in check.
Answer a few questions about your symptoms to help you have more productive conversations with your gastroenterologist.
Find answers to frequently asked questions about RINVOQ >
Team up with a specialist who can help you go beyond temporary symptom relief.
RINVOQ UC clinical study results won't back down—neither should you.
RINVOQ is a prescription medicine used to treat adults with moderate to severe ulcerative colitis when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children with ulcerative colitis.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about RINVOQ?
RINVOQ may cause serious side effects, including:
Do not take RINVOQ if you are allergic to upadacitinib or any of the ingredients in RINVOQ. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.
What should I tell my HCP BEFORE starting RINVOQ?
Tell your HCP if you:
Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects.
Especially tell your HCP if you take:
If you are not sure if you are taking any of these medicines, ask your HCP or pharmacist.
What should I avoid while taking RINVOQ?
Avoid food or drink containing grapefruit during treatment with RINVOQ as it may increase the risk of side effects.
What should I do or tell my HCP AFTER starting RINVOQ?
What are other possible side effects of RINVOQ?
Common side effects include upper respiratory tract infections (common cold, sinus infections), shingles (herpes zoster), herpes simplex virus infections (including cold sores), bronchitis, nausea, cough, fever, acne, headache, increased blood levels of creatine phosphokinase, allergic reactions, inflammation of hair follicles, stomach-area (abdominal) pain, increased weight, flu, tiredness, lower number of certain types of white blood cells (neutropenia, lymphopenia, leukopenia), muscle pain, flu-like illness, rash, increased blood cholesterol levels, increased liver enzyme levels, pneumonia, low number of red blood cells (anemia), and infection of the stomach and intestine (gastroenteritis).
A separation or tear to the lining of the back part of the eye (retinal detachment) has happened in people with atopic dermatitis treated with RINVOQ. Call your HCP right away if you have any sudden changes in your vision during treatment with RINVOQ.
Some people taking RINVOQ may see medicine residue (a whole tablet or tablet pieces) in their stool. If this happens, call your healthcare provider.
These are not all the possible side effects of RINVOQ.
How should I take RINVOQ?
RINVOQ is taken once a day with or without food. Do not split, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets.
This is the most important information to know about RINVOQ. For more information, talk to your HCP.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
USES
RINVOQ is a prescription medicine used to treat:
It is not known if RINVOQ is safe and effective in children with juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn’s disease.
RINVOQ is safe and effective in children 12 years of age and older weighing at least 88 pounds (40 kg) with atopic dermatitis.
It is not known if RINVOQ is safe and effective in children under 12 years of age with atopic dermatitis.
If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.
US-RNQ-220259
Please see the Full Prescribing Information, including the Medication Guide, for RINVOQ.
Legal Notices/Privacy Policy. © 2022 AbbVie. All rights reserved. If you have any questions about AbbVie's RINVOQ.com website that have not been answered, click here. This website and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient.
US-RNQR-190268
